MK-6482
Total Payments
$5.2M
Transactions
2,447
Doctors
21
Companies
1
Payment Trends by Year
| Year | Amount | Transactions | Doctors |
|---|---|---|---|
| 2020 | $4.2M | 2,344 | 21 |
| 2019 | $1.0M | 103 | 1 |
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Unspecified | $5.1M | 2,356 | 98.1% |
| Consulting Fee | $90,525 | 51 | 1.7% |
| Travel and Lodging | $4,342 | 19 | 0.1% |
| Food and Beverage | $1,298 | 20 | 0.0% |
| Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | $14.99 | 1 | 0.0% |
Payments by Type
Research
$5.1M
2,356 transactions
General
$96,180
91 transactions
Research Studies & Clinical Trials
| Study Name | Sponsor | Amount | Doctors |
|---|---|---|---|
| An Open-Label Phase 2 Study to Evaluate PT2977 For The Treatment of Von Hippel-Lindau Disease-Associated Renal Cell Carcinoma | Merck Sharp & Dohme Corporation | $1.3M | 0 |
| An Open-label, Randomized Phase 3 Study of MK-6482 Versus Everolimus in Participants with Advanced Renal Cell Carcinoma That Has Progressed After Prior PD-1,L1 and VEGF-Targeted Therapies | Merck Sharp & Dohme Corporation | $1.2M | 0 |
| A Phase 2 Trial of PT2977 in Combination with Cabozantinib in Patients with Advanced Clear Cell Renal Cell Carcinoma | Merck Sharp & Dohme Corporation | $1.2M | 0 |
| A Phase 1, Dose-Escalation and Expansion Trial of PT2977, A HIF-2a Inhibitor, In Patients with Advanced Solid Tumors | Merck Sharp & Dohme Corporation | $647,653 | 0 |
| A Phase 2 Trial of PT2977 in Combination with Cabozantinib in Patients with Advanced Renal Cell Carcinoma | Merck Sharp & Dohme Corporation | $376,208 | 0 |
| Phase 2 Study of MK-6482 in Participants With Advanced Renal Cell Carcinoma | Merck Sharp & Dohme Corporation | $208,781 | 0 |
| Ph2 Trial of PT2977 in combo with Cabozantinib in Adv Renal Cell Carcinoma | Merck Sharp & Dohme Corporation | $68,965 | 0 |
| An Open-label, Randomized, Phase 3 Study of MK-6482 in Combination with Lenvatinib MK-7902 vs Cabozantinib for Second-line or Third-line Treatment in Participants with Advanced Renal Cell Carcinoma Who Have Progressed After Prior Anti-PD-1,L1 Combination Regimen | Merck Sharp & Dohme Corporation | $63,560 | 0 |
| A Study to Evaluate the Effect of Multiple Doses of MK-6482 on the Pharmacokinetics of Midazolam in Healthy Participants | Merck Sharp & Dohme Corporation | $38,337 | 0 |
| A Study to Assess the Effect of Food on the Pharmacokinetics of the MK-6482 Final Market Image Tablet Formulation in Healthy Participants | Merck Sharp & Dohme Corporation | $31,701 | 0 |
| A Study to Investigate the Absorption, Metabolism, Excretion, and Mass Balance of MK-6482 in Healthy Adults | Merck Sharp & Dohme Corporation | $509.48 | 0 |
Top Doctors Receiving Payments for MK-6482
| Doctor | Specialty | Location | Total | Records |
|---|---|---|---|---|
| Unknown | — | Philadelphia, PA | $5.1M | 2,361 |
| , M.D | Medical Oncology | Houston, TX | $47,000 | 2 |
| , M.D | Urology | Woodbury, MN | $5,000 | 1 |
| , MD | Medical Oncology | New York, NY | $3,750 | 2 |
| , M.D | Medical Oncology | New Orleans, LA | $3,750 | 3 |
| , M.D | Medical Oncology | Charlottesville, VA | $3,750 | 4 |
| , MD | Hematology & Oncology | Cleveland, OH | $3,500 | 3 |
| , MD | Nuclear Radiology | Abington, PA | $3,390 | 7 |
| , MD | Diagnostic Radiology | Philadelphia, PA | $2,910 | 5 |
| , MD | Medical Oncology | Boston, MA | $2,500 | 1 |
| , MD | Diagnostic Radiology | Philadelphia, PA | $2,430 | 5 |
| , M.D | Medical Oncology | Houston, TX | $2,000 | 1 |
| , MD | Medical Oncology | Washington, DC | $2,000 | 1 |
| , MD | Internal Medicine | Los Angeles, CA | $2,000 | 1 |
| , MD | Body Imaging | New York, NY | $1,890 | 4 |
| , M.D | Endocrinology, Diabetes & Metabolism | Houston, TX | $1,875 | 1 |
| , MD, PHD | Hematology & Oncology | Marietta, GA | $1,624 | 10 |
| , MD | Hematology & Oncology | Birmingham, AL | $1,448 | 10 |
| , M.D | Medical Oncology | Detroit, MI | $1,316 | 10 |
| , M.D | Diagnostic Radiology | San Diego, CA | $1,230 | 5 |
| , M.D., PH.D | Student in an Organized Health Care Education/Training Program | Nashville, TN | $1,141 | 9 |
| , MD | Hematology & Oncology | Boston, MA | $124.92 | 1 |
Ad
Manufacturing Companies
Product Information
- Type Drug
- Total Payments $5.2M
- Total Doctors 21
- Transactions 2,447
About MK-6482
MK-6482 is a drug associated with $5.2M in payments to 21 healthcare providers, recorded across 2,447 transactions in the CMS Open Payments database. The primary manufacturer is Merck Sharp & Dohme Corporation.
Payment data is available from 2019 to 2020. In 2020, $4.2M was paid across 2,344 transactions to 21 doctors.
The most common payment nature for MK-6482 is "Unspecified" ($5.1M, 98.1% of total).
MK-6482 is associated with 11 research studies, including "An Open-Label Phase 2 Study to Evaluate PT2977 For The Treatment of Von Hippel-Lindau Disease-Associated Renal Cell Carcinoma" ($1.3M).